CN104489674B - A kind of composition and its preparation for alleviating exercise induced fatigue - Google Patents
A kind of composition and its preparation for alleviating exercise induced fatigue Download PDFInfo
- Publication number
- CN104489674B CN104489674B CN201410784188.3A CN201410784188A CN104489674B CN 104489674 B CN104489674 B CN 104489674B CN 201410784188 A CN201410784188 A CN 201410784188A CN 104489674 B CN104489674 B CN 104489674B
- Authority
- CN
- China
- Prior art keywords
- parts
- eucommia leaf
- leaf extract
- composition
- american ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 54
- 241000208688 Eucommia Species 0.000 claims abstract description 53
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 49
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000000605 extraction Methods 0.000 claims abstract description 13
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 7
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 7
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 7
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 7
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 7
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 7
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 7
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 235000021552 granulated sugar Nutrition 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- -1 isomaltoketose Chemical compound 0.000 claims description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- 239000012259 ether extract Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 13
- 239000002253 acid Substances 0.000 abstract description 11
- 102100026189 Beta-galactosidase Human genes 0.000 abstract description 10
- 108010059881 Lactase Proteins 0.000 abstract description 10
- 108010005774 beta-Galactosidase Proteins 0.000 abstract description 10
- 229940116108 lactase Drugs 0.000 abstract description 10
- 230000002929 anti-fatigue Effects 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 229930182490 saponin Natural products 0.000 abstract description 3
- 150000007949 saponins Chemical class 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 238000004806 packaging method and process Methods 0.000 abstract description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 239000013642 negative control Substances 0.000 description 21
- 239000013641 positive control Substances 0.000 description 20
- 230000033001 locomotion Effects 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 239000011122 softwood Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 244000237330 gutta percha tree Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 208000007976 Ketosis Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- NRTLIYOWLVMQBO-UHFFFAOYSA-N 5-chloro-1,3-dimethyl-N-(1,1,3-trimethyl-1,3-dihydro-2-benzofuran-4-yl)pyrazole-4-carboxamide Chemical compound C=12C(C)OC(C)(C)C2=CC=CC=1NC(=O)C=1C(C)=NN(C)C=1Cl NRTLIYOWLVMQBO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of composition and its preparation for alleviating exercise induced fatigue, the composition includes the following each component of weight portion：20~90 parts of eucommia leaf extract, 10~60 parts of American Ginseng.The beneficial effect of composition of the invention is：Eucommia leaf extract Content of Chlorogenic Acid is more than or equal to 25%, and chlorogenic acid has good removing free radical, antioxidation, and its antifatigue mechanism is relevant with its inoxidizability；American Ginseng contains American ginseng saponin in said composition, and its content is more than or equal to 8%.Both eucommia leaf extract and American Ginseng compatibility, can effectively reduce postexercise heart rate and blood lactase acid level, so as to play antifatigue effect；Product prepared by the present invention is easy to carry, simply eaten.Extraction and dried process of the natural plant component by science, make this product after packaging be easy to carry about with one.This product can various ways eat, and method is simple.
Description
Technical field
The invention belongs to field of health care food, it is related to a kind of composition and its preparation for alleviating exercise induced fatigue.
Background technology
Exercise induced fatigue refers to that its function can not be maintained at a certain specified level and/or can not remain a certain predetermined by body
Exercise intensity.During sportsman carries out training, when training strength and training burden are constantly close to human body limit water
Usually, body just easily produces fatigue.The fatigue of appropriateness is temporary transient, is the effective stimulus for improving body movement ability, and can
Eliminated with by means such as nutrition, sleeps.And if degree of fatigue is too deep or fails to be recovered in time, gradually accumulating, Jiu Huizao
Into body fatigue.This performance that can not only influence sportsman's technology and the raising of sports level, also can be to the body of sportsman
Body health causes high risks, such as metabolic disorder, endocrinopathy, immunity reduction, neurasthenia.Therefore, only actively
The mechanism of exercise induced fatigue is inquired into, and finds safely and effectively prophylactico-therapeutic measures, sportsman could be helped to eliminate motility tired
Labor, promotion is healthy, so as to improve sports achievement.
Lactic acid is that, in human body strenuous exercise, oxygen supply is not enough, and sugar is generated by series reaction, is that glycolysis is supplied
The final product of energy.Blood lactase acid is that glycogen is produced by glycolysis energy supply in skeletal muscle.It is tired that the accumulation of lactic acid produces human body
Labor, causes locomitivity to decline.Bulk deposition can suppress the normal activity of myoneural to lactic acid in vivo, and muscle can occur quickly
Fatigue.
In the common fatigue-relieving health products of existing market, products material composition is more single, and excessively emphasizes product
Curative effect, and ignore absorption and the food-safety problem of human body, it is impossible to fully meet the demand of various people.And some Chinese medicines,
Effect with blood lactase acid level after good raising endurance, reduction motion, can effectively alleviate sports fatigue.Therefore, by Chinese medicine
Combined with traditional anti-fatigue nutrient condition, there is provided a kind of multi-faceted anti-Fatigue Composition has practical significance.At present, there is not yet
Shared to eucommia leaf extract and American Ginseng both active components, and the related report in terms of alleviate exercise induced fatigue
Road.
The content of the invention
The first object of the present invention is to provide a kind of composition for alleviating exercise induced fatigue, can effectively alleviate due to motion
And the fatigue for producing.
The composition for alleviating exercise induced fatigue of the present invention, including the following each component of weight portion：Eucommia leaf extract
20~90 parts, 10~60 parts of American Ginseng.
Preferably, the composition includes the following each component of weight portion：30~60 parts of the eucommia leaf extract, the West
20~50 parts of ginseng.
In above-mentioned composition,
Weight portion of the present invention can be unit of weight known to the field of medicaments such as μ g, mg, g, kg.
In the present invention, the eucommia leaf extract Content of Chlorogenic Acid is more than or equal to 25%.
American Ginseng of the present invention is used as medicine with former powder, former powder can use commercially available product, or purchase medicinal material crushed, mistake
Sieve and obtain.
Eucommia leaf extract of the present invention can use commercially available product, or be obtained by conventional method extraction, in order that this
The effect of the composition of invention more preferably, is more beneficial for fatigue-relieving.Eucommia leaf extract of the present invention is preferably by with lower section
Method is obtained：
1) folium cortex eucommiae is obtained into Eucommia Leaf Powder after dried, crushed, crosses 50~100 mesh sieves, by the solid volume ratio (4~6) of liquid:1
Petroleum ether is added to extract 0.5~1.5h of ultrasonic wave extraction after 10~14 h, filtering, filter residue repeats to extract once, merging filtrate；
2) take step 1) gained filter residue by liquid consolidate volume ratio (8~12):1 adds the alcohol steep of volume fraction 40%~60%
0.5~1.5h of ultrasonic wave extraction after overnight, filtering, filter residue is repeated to extract twice, merging filtrate；
3) under the conditions of 50~70 DEG C, 0.05~0.10MPa be concentrated under reduced pressure step 1) and step 2) gained filtrate to do,
20~40 DEG C, be vacuum dried into powder under 0.5~1.5 vacuum degree condition, obtain final product the eucommia leaf extract.
It is highly preferred that the eucommia leaf extract is obtained by the following method：
1) folium cortex eucommiae is obtained into Eucommia Leaf Powder after dried, crushed, crosses 80 mesh sieves, by the solid volume ratio 5 of liquid:1 adds petroleum ether
Ultrasonic wave extraction 1h after extraction 12h, filtering, filter residue repeats to extract once, merging filtrate；
2) take step 1) gained filter residue by liquid consolidate volume ratio 10:1 adds the alcohol steep of volume fraction 50% overnight rear ultrasound
Ripple extracts 1h, filtering, and filter residue is repeated to extract twice, merging filtrate；
3) be concentrated under reduced pressure step 1 under the conditions of 60 DEG C, 0.09MPa) and step 2) gained filtrate to dry, 30 DEG C, 1 very
Powder is vacuum dried under the conditions of reciprocal of duty cycle, the eucommia leaf extract is obtained final product.
Another object of the present invention is to provide the preparation containing above-mentioned composition, and the preparation includes the composition and pharmacy
Upper acceptable carrier or diluent.
The pharmaceutically acceptable carrier or diluent are selected from xylitol, D-sorbite, isomalt, different malt
Ketose, mannitol, ethanol, microcrystalline cellulose, lactose, HPMC, soybean oil, starch, white granulated sugar or magnesium stearate
In one or more.
The pharmaceutically acceptable carrier or diluent are preferably starch, lactose, magnesium stearate, white granulated sugar and different malt
One or more in ketose.
Preparation of the present invention is preferably solid pharmaceutical preparation；The solid pharmaceutical preparation is tablet, capsule, pulvis or soft capsule.
As preferred scheme, preparation of the present invention, including following each component by weight：Folium cortex eucommiae is extracted
20~90 parts of thing, 20~60 parts of American Ginseng, 50~200 parts of lactose, 43.6~57.2 parts of microcrystalline cellulose, magnesium stearate 2.8~
6.4 parts.Using the preparation of above-mentioned preferred scheme, easily it is absorbed by the body, drug effect release is fast.
Used as preferred scheme, the preparation includes following each component by weight：Eucommia leaf extract 90
Part, 60 parts of American Ginseng, 200 parts of lactose, 43.6 parts of microcrystalline cellulose, 6.4 parts of magnesium stearate.
The present invention also provides the composition or described preparation answering in the health products for alleviating exercise induced fatigue are prepared
With.
The beneficial effect of composition of the invention is：
1st, eucommia leaf extract Content of Chlorogenic Acid is more than or equal to 25%, and chlorogenic acid has good removing free radical, resists
Oxidation, its antifatigue mechanism is relevant with its inoxidizability；American Ginseng contains American ginseng saponin in said composition, and its content is more than
Equal to 8%.Both eucommia leaf extract and American Ginseng compatibility, can effectively reduce postexercise heart rate and blood lactase acid level level,
So as to play antifatigue effect.
2nd, the product that prepared by the present invention is easy to carry, simply eaten.Natural plant component is by the extraction of science and dry
Dry treatment, makes the product after packaging be easy to carry about with one.The present invention can various ways eat, and method is simple.
Specific embodiment
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.If not specializing, embodiment
In the conventional meanses that are well known to those skilled in the art of technological means used, it is raw materials used to be commercial goods.
For the buying producer of eucommia leaf extract, American Ginseng be in order to further illustrate realizability of the invention, but
It is that should not be taken to limit the scope of the present invention.
Raw material of the present invention：Eucommia leaf extract is purchased from Changsha Shang He bio tech ltd, is containing weight/mass percentage composition
35% chlorogenic acid；American Ginseng is purchased from Jilin Hongjiu Biotech Co., Ltd., is 10% containing weight/mass percentage composition
American ginseng total saponins.The raw material of purchase can also be the product of other conventional specifications, and the specification effect limited with the present invention is more preferable.
American Ginseng described in the embodiment of the present invention is used as medicine with former powder, and former powder can use commercially available product, or purchase medicinal material to enter
Row is crushed, sieves and obtain.
Eucommia leaf extract of the present invention can use commercially available product, or be obtained by conventional method extraction, in order that this
The effect of the composition of invention more preferably, is more beneficial for fatigue-relieving.Eucommia leaf extract of the present invention is preferably by with lower section
Method is obtained and is：
1) folium cortex eucommiae is obtained into Eucommia Leaf Powder after dried, crushed, crosses 80 mesh sieves, by the solid volume ratio 5 of liquid:1 adds petroleum ether
The h of ultrasonic wave extraction 1 after 12 h is extracted, is filtered, filter residue repeats to extract once, merging filtrate；
2) take step 1) gained filter residue by liquid consolidate volume ratio 10:1 adds the alcohol steep of volume fraction 50% overnight rear ultrasound
Ripple extracts 1h, filtering, and filter residue is repeated to extract twice, merging filtrate；
3) be concentrated under reduced pressure step 1 under the conditions of 60 DEG C, 0.09MPa) and step 2) gained filtrate to dry, 30 DEG C, 1 very
Powder is vacuum dried under the conditions of reciprocal of duty cycle, the eucommia leaf extract is obtained final product.
The extracting method of above-mentioned folium cortex eucommiae is optimal scheme, in the specific implementation, the technological parameter of each step according to
Need, can be adjusted according to the preferred scheme of the extracting method of folium cortex eucommiae in the content of the invention.
Embodiment 1：Capsule
1st, the present embodiment prescription：Eucommia leaf extract 600g, American Ginseng 400g, prepare 2000,0.5g/.
2nd, preparation method：
1) eucommia leaf extract, American Ginseng are weighed according to formula, 40 mesh sieves is crossed respectively, it is standby；
2) above-mentioned former, auxiliary material is well mixed by the equivalent method of progressively increasing, is poured into capsule filling mould, filling capsule, polishing,
Packing.
3rd, specification：300mg containing eucommia leaf extract, American Ginseng 200mg in every capsule.
4th, taking dose：Oral 3 times, every time 2 daily.
Embodiment 2：Pulvis
1st, the present embodiment prescription：Eucommia leaf extract 8000g, American Ginseng 1500g, white granulated sugar 9000g, isomaltoketose
1500g, prepares 2000 bags, 10g/ bags.
2nd, preparation method：
1) eucommia leaf extract, American Ginseng, white granulated sugar and isomaltoketose are weighed according to prescription, 40 mesh sieves is crossed respectively, it is standby
With；
2) above-mentioned former, auxiliary material is well mixed by the equivalent method of progressively increasing, is dispensed.
3rd, specification：Every bag of 4g containing eucommia leaf extract, American Ginseng 750mg.
4th, instructions of taking：Take 3 times, every time 1 bag daily.
Embodiment 3：Tablet
1st, the present embodiment prescription：It is eucommia leaf extract 200g, American Ginseng 600g, lactose 600g, microcrystalline cellulose 572g, hard
Fatty acid magnesium 28g, prepares 2500,0.8g/ pieces.
2nd, preparation method：
Each composition is weighed respectively, and above-mentioned former, auxiliary material (composition in addition to magnesium stearate) is then progressively increased into method mixing by equivalent
It is even, using water as adhesive, softwood processed；Particle is made in oscillating granulator by above-mentioned softwood through 14 eye mesh screens, by particle
Insert in multi-functional boiling drier, in 50 DEG C of fluidized dryings about 40 minutes, control pellet moisture 5%, whole grain, then
Magnesium stearate is added in grain, total mixed, compressing tablet, packing；
3rd, specification：Every 80mg containing eucommia leaf extract, American Ginseng 240mg.
4th, taking dose：Three times a day, 2 are each taken.
Embodiment 4：Tablet
1st, the present embodiment prescription：Eucommia leaf extract 900g, American Ginseng 600g, lactose 2000g, microcrystalline cellulose 436g,
Magnesium stearate 64g, prepares 5000,0.8g/ pieces.
2nd, preparation method：
Each composition is weighed respectively, and above-mentioned former, auxiliary material (composition in addition to magnesium stearate) is then progressively increased into method mixing by equivalent
It is even, using water as adhesive, softwood processed；Particle is made in oscillating granulator by above-mentioned softwood through 14 eye mesh screens, by particle
Insert in multi-functional boiling drier, in 50 DEG C of fluidized dryings about 40 minutes, control pellet moisture 5%, whole grain, then
Magnesium stearate is added in grain, total mixed, compressing tablet, packing；
3rd, specification：Every 180mg containing eucommia leaf extract, American Ginseng 120mg.
4th, taking dose：Three times a day, 2 are each taken.
Embodiment 5：Tablet
1st, the present embodiment prescription：It is eucommia leaf extract 800g, American Ginseng 200g, lactose 500g, microcrystalline cellulose 436g, hard
Fatty acid magnesium 64g, prepares 2500,0.8g/ pieces.
2nd, preparation method：
Each composition is weighed respectively, and above-mentioned former, auxiliary material (composition in addition to magnesium stearate) is then progressively increased into method mixing by equivalent
It is even, using 1.2kg water as adhesive, softwood processed；Particle is made in oscillating granulator by above-mentioned softwood through 14 eye mesh screens, will
Particle is inserted in multi-functional boiling drier, in 50 DEG C of fluidized dryings about 40 minutes, control pellet moisture 5%, whole grain, then
Magnesium stearate is added in particle, total mixed, compressing tablet, packing；
3rd, specification：Every 320mg containing eucommia leaf extract, American Ginseng 80mg.
4th, taking dose：Daily 2 times, each take 2.
Embodiment 6：Capsule
The present embodiment is differed only in embodiment 1：Eucommia leaf extract 900g, American Ginseng 100g.
Embodiment 7：Tablet
The present embodiment is differed only in embodiment 3：Eucommia leaf extract 600g, American Ginseng 200g.
Embodiment 8：Tablet
The present embodiment is differed only in embodiment 5：Eucommia leaf extract 600g, American Ginseng 400g.
Embodiment 9：Tablet
The present embodiment is differed only in embodiment 5：Eucommia leaf extract 375g, American Ginseng 625g.
Embodiment 10：Tablet
The present embodiment is differed only in embodiment 5：Eucommia leaf extract 500g, American Ginseng 500g.
Experimental example 1：Experiment on probation
1st, experimental subjects
With certain sport university 64 man's track riders (average age 18.5 ± 0.67 years old) as research object.
2nd, experiment packet
Packet：64 subjects are randomly divided into 8 groups,
Negative control group (N=8)：Starch capsule is taken as placebo, is taken daily 3 times, every time 2；
Positive controls 1：Take eucommia leaf extract tablet (tablet composition with preparation method with reference to embodiment 5, its
Difference with embodiment 5 is：Without American Ginseng, the weight of eucommia ulmoides extracts is adjusted to 1250g, and every is extracted containing folium cortex eucommiae
Thing 500mg), take daily 2 times, 2 tablets once；
Positive controls 2：Take Western ginseng tablet (tablet composition with preparation method with reference to embodiment 5, itself and implementation
The difference of example 5 is：Without eucommia ulmoides extracts, the weight of American Ginseng is adjusted to 1250g, and every contains American Ginseng 500mg) daily
Take 2 times, 2 tablets once；
Positive controls 3 take the product of embodiment 1 in disclosed patent of invention CN104127577A, are to be extracted containing matrimony vine
The capsule of thing, Ganodenna Lucidum P.E and American Ginseng.Wherein, the weight of each bulk drug is in every capsule：Fructus lycii P.E
200mg, Ganodenna Lucidum P.E 80mg, American Ginseng 170mg, 4/day；
Experimental group 1：Take composition tablet group of the invention (embodiment 3, every 80mg containing eucommia leaf extract, the West
Ginseng 240mg), take daily 3 times, 2 tablets once；
Experimental group 2：Take composition tablet group of the invention (embodiment 4, every 180mg containing eucommia leaf extract, the West
Ginseng 120mg), take daily 3 times, 2 tablets once；
Experimental group 3：Take composition tablet group of the invention (embodiment 5, every 320mg containing eucommia leaf extract, the West
Ginseng 80mg) take 2 times daily, 2 tablets once；
Experimental group 4：Take composition tablet group of the invention (embodiment 8, every 240mg containing eucommia leaf extract, the West
Ginseng 160mg), take daily 2 times, 2 tablets once；
Continuously take 4 weeks.Prohibit during whole experiment and take other antifatigue food and medicine.
3rd, experimental technique
It is required that subject comes venous blood when laboratory takes peace and quiet on an empty stomach before the test, carried out before motion exercise load (
Moved on Monark power meters), first limber up 1min (0 load) is then started to pedal with 50W power, is progressively incremented by negative
Lotus, reaches 70%Hrmax (determined by trial test and drawn) for 3 minutes or so, is not hereafter further added by load, continues 60 points to pedal
Clock.Centre of motion rate is monitored using Polar tables.The temperature and humidity of Control release room.Subject after 4 weeks nutriment are taken,
Tested again.
4th, index and method
Test index：Ear blood is taken within the 3rd, 9,15 minutes after immediate postexercise, motion survey lactic acid.After immediate postexercise, motion
Measurement in 3rd minute recovers heart rate.
Method of testing：Blood lactase acid is determined using YSI1500SPORT LACTATE ANALYZER, and method is Enzyme Electrode.
5th, result statistics
Data processing uses SPSS13.0 softwares, and all data are represented with means standard deviation, using variance and pairing T
The method of inspection.
6th, experimental result
The comparing of 6.1 blood lactate concentrations：The results are shown in Table 1
Table 1：Blood lactate concentration change (mmol/l) after each group motion
Compared with negative control group, #p<0.05；##p<0.01；Compared with positive controls, * p<0.05；**p<0.01.
Find out from the result of table 1：
Immediate postexercise, the blood lactate concentration of positive controls is less than negative control group, but does not produce conspicuousness poor
It is different；And experimental group blood lactate concentration conspicuousness reduction compared with negative control group, and experimental group blood lactase acid be substantially less than it is positive right
According to group (p<0.05)；The blood lactate concentration of positive controls 3 is less than negative control group and positive controls 1,2, and is higher than each experiment
Group, but there was no significant difference；
Motion terminates rear 3min, and each group blood lactase acid reaches maximum, and positive controls are substantially less than negative control group (p<
0.05)；Experimental group has different degrees of reduction (p ＜ 0.05, p compared with negative control group<0.01), experimental group is right with the positive
Compared according to group, blood lactate concentration conspicuousness reduction (p<0.05), the blood lactase acid of experimental group 2 is less than other experimental groups；
Motion terminates rear 9min, and compared with negative control group, blood lactate concentration has reduction trend but without aobvious to positive controls
Write sex differernce；Compared with negative control group, blood lactate concentration conspicuousness reduces (p to experimental group<0.05), wherein experimental group 2 extremely shows
Write and be less than negative control group (p ＜ 0.01), and substantially less than positive controls (p ＜ 0.05), experimental group 1,3,4 is less than positive right
According to group but there was no significant difference；
Motion terminates rear 15min, and negative control group, positive controls and experimental group return to level during peace and quiet.
Lactic acid is the acidic metabolite that energy substance anaerobic metabolism is obtained in vivo in motion process, a large amount of acidic materials products
It is tired, cause muscle, the swollen and metal fatigue of joint acid.The composition of present invention offer is provided, internal blood lactase acid is helped speed up
Removing speed, improves stamina of speed level, and effect is better than exclusive use eucommia ulmoides extracts or American Ginseng.
Recover within 3 minutes the comparing of heart rate after 6.2 immediate postexercises and end：The results are shown in Table 2
Table 2：The heart rate (beat/min) recovered for 3 minutes after immediate postexercise and end
| Packet | Immediate postexercise | Motion terminates rear 3min |
| Negative control group | 142.88±1.28 | 125.68±1.62 |
| Positive controls 1 | 138.45±0.87 | 121.26±0.58 |
| Positive controls 2 | 139.22±1.23 | 120.67±1.83 |
| Positive controls 3 | 136.52±1.35 | 119.64±1.72 |
| Experimental group 1 | ||
| Experimental group 2 | ||
| Experimental group 3 | ||
| Experimental group 4 |
Compared with negative control group, #p<0.05；##p<0.01；Compared with positive controls, * p ＜ 0.05, * * p ＜
0.01。
As can be seen from Table 2：
Immediate postexercise, positive controls heart rate is less than negative control group, but there was no significant difference；Experiment 1-4
Each group heart rate is less than negative control group, and the wherein pole of experimental group 2 is substantially less than negative control group (p<0.01), experimental group 1,
3rd, 4 it is substantially less than negative control group (p ＜ 0.05)；Experimental group is less than positive controls, but there was no significant difference.
Motion terminates rear 3min, and each group heart rate is in reduction trend, and positive controls are less than negative control group but without significantly
Sex differernce；Experimental group 1,3,4 is substantially less than negative control group (p ＜ 0.05), and the pole of experimental group 2 is substantially less than negative control group (P<
0.01)；Experimental group 2 is substantially less than positive controls (p ＜ 0.05).
Heart rate resume speed is fast, shows that experimental group subject motion endurance is good, and locomitivity is strong.It can therefore be seen that real
The antifatigue effect for testing group subject is better than negative control group and positive controls.The antifatigue effect of the composition of experimental group 2
It is really best.
Equally, other embodiment of the present invention or compatibility are tested, effect is similar with experimental group 1-4.
3rd, conclusion
From the point of view of whole experiment process, the composition that the present invention is provided has accelerates subject's blood lactase acid resume speed,
Heart rate recovers also fast effect, and these are all advantageous for extending the key factor of exercise tolerance, and then improve locomitivity, have
Synergistic function.
Although above the present invention is described in detail with a general description of the specific embodiments,
On the basis of the present invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Cause
This, these modifications or improvements, belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (9)
1. it is a kind of alleviate exercise induced fatigue composition, it is characterised in that：It is made up of the component of following weight portion：Folium cortex eucommiae is extracted
20~90 parts of thing, 10~60 parts of American Ginseng；The eucommia leaf extract Content of Chlorogenic Acid is more than or equal to 25%.
2. composition according to claim 1, it is characterised in that：It is made up of the component of following weight portion：Folium cortex eucommiae is extracted
30~60 parts of thing, 20~50 parts of American Ginseng.
3. composition according to claim 1 and 2, it is characterised in that：The eucommia leaf extract is obtained by the following method
Arrive：
1) folium cortex eucommiae is obtained into Eucommia Leaf Powder after dried, crushed, crosses 50~100 mesh sieves, by the solid volume ratio (4~6) of liquid:1 adds
Petroleum ether extracts 0.5~1.5h of ultrasonic wave extraction after 10~14h, filtering, and filter residue repeats to extract once, merging filtrate；
2) take step 1) gained filter residue by liquid consolidate volume ratio (8~12):1 adds the alcohol steep of volume fraction 40%~60% overnight
0.5~1.5h of ultrasonic wave extraction, is filtered afterwards, and filter residue is repeated to extract twice, merging filtrate；
3) be concentrated under reduced pressure step 1 under the conditions of 50~70 DEG C, 0.05~0.10MPa) and step 2) gained filtrate to doing, 20~
40 DEG C, be vacuum dried into powder under 0.5~1.5 vacuum degree condition, obtain final product the eucommia leaf extract.
4. composition according to claim 3, it is characterised in that：The eucommia leaf extract is obtained by the following method：
1) folium cortex eucommiae is obtained into Eucommia Leaf Powder after dried, crushed, crosses 80 mesh sieves, by the solid volume ratio 5 of liquid:1 adds petroleum ether extraction
Ultrasonic wave extraction 1h after 12h, filtering, filter residue repeats to extract once, merging filtrate；
2) take step 1) gained filter residue by liquid consolidate volume ratio 10:Overnight rear ultrasonic wave is carried 1 addition volume fraction 50% alcohol steep
1h is taken, is filtered, filter residue is repeated to extract twice, merging filtrate；
3) under the conditions of 60 DEG C, 0.09MPa be concentrated under reduced pressure step 1) and step 2) gained filtrate to do, in 30 DEG C, 1 vacuum
Under the conditions of be vacuum dried into powder, obtain final product the eucommia leaf extract.
5. a kind of preparation, it is characterised in that the active component of the preparation is the combination any one of claim 1-4
Thing, the preparation also includes pharmaceutically acceptable carrier or diluent.
6. preparation according to claim 5, it is characterised in that：The pharmaceutically acceptable carrier or diluent are selected from wood
Sugar alcohol, D-sorbite, isomalt, isomaltoketose, mannitol, ethanol, microcrystalline cellulose, lactose, hydroxypropyl are fine
One or more in dimension element, soybean oil, starch, white granulated sugar or magnesium stearate.
7. preparation according to claim 6, it is characterised in that：Including following each component by weight：Folium cortex eucommiae
20~90 parts of extract, 20~60 parts of American Ginseng, 50~200 parts of lactose, 43.6~57.2 parts of microcrystalline cellulose, magnesium stearate
2.8~6.4 parts.
8. preparation according to claim 7, it is characterised in that：The preparation includes following each group by weight
Point：90 parts of eucommia leaf extract, 60 parts of American Ginseng, 200 parts of lactose, 43.6 parts of microcrystalline cellulose, 6.4 parts of magnesium stearate.
9. composition any one of claim 1-4 or the preparation any one of claim 5-8 are preparing alleviation
Application in the health products of exercise induced fatigue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410784188.3A CN104489674B (en) | 2014-12-16 | 2014-12-16 | A kind of composition and its preparation for alleviating exercise induced fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410784188.3A CN104489674B (en) | 2014-12-16 | 2014-12-16 | A kind of composition and its preparation for alleviating exercise induced fatigue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104489674A CN104489674A (en) | 2015-04-08 |
| CN104489674B true CN104489674B (en) | 2017-06-16 |
Family
ID=52931207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410784188.3A Active CN104489674B (en) | 2014-12-16 | 2014-12-16 | A kind of composition and its preparation for alleviating exercise induced fatigue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104489674B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108310294A (en) * | 2018-03-29 | 2018-07-24 | 扬州工业职业技术学院 | A kind of method quickly to regain one's strength after sports |
| CN108339077A (en) * | 2018-03-29 | 2018-07-31 | 扬州工业职业技术学院 | A method of alleviating aching pain of muscles after strenuous exercise |
| CN109938269A (en) * | 2019-03-18 | 2019-06-28 | 普正药业集团股份有限公司 | A kind of Cortex Eucommiae Gallus domesticlus brisson noodles and preparation method thereof |
| CN110193034A (en) * | 2019-05-06 | 2019-09-03 | 普正药业集团股份有限公司 | A kind of eucommia leaf extract and its application in alleviation physical fatigue product |
| CN110663949A (en) * | 2019-11-20 | 2020-01-10 | 江西普正制药股份有限公司 | Health product containing folium Eucommiae with antifatigue effect and its preparation method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050027452A (en) * | 2003-09-15 | 2005-03-21 | 주식회사 이노팜 | Composition for inhibiting obesity |
| CN102225969A (en) * | 2011-04-07 | 2011-10-26 | 贵州大学 | Polysaccharide from Eucommia ulmoides leaves with anti-complement activity, method of extracting, separating and purifying the same |
| CN102579836B (en) * | 2012-03-02 | 2013-06-12 | 安徽圣农生物科技股份有限公司 | Traditional Chinese medical dendrobium huoshanense composition and preparation method thereof |
| CN103355459A (en) * | 2013-08-06 | 2013-10-23 | 北京绿源求证科技发展有限责任公司 | Food health tea granules used for preventing hypertension |
-
2014
- 2014-12-16 CN CN201410784188.3A patent/CN104489674B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104489674A (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104489674B (en) | A kind of composition and its preparation for alleviating exercise induced fatigue | |
| CN103960568B (en) | A kind of general ginsenoside chewable tablets and preparation method thereof | |
| CN104524186B (en) | A kind of anti-fatigue medicament and preparation method thereof | |
| CN104432063B (en) | Composition for alleviating athletic fatigue and preparation method thereof | |
| CN105105116A (en) | Health food with effects of relieving physical fatigue and enhancing immunity and preparation method of health food | |
| CN107319086A (en) | A kind of matrimony vine spun gold emperor chrysanthemum pressed candy and preparation method thereof | |
| CN105494844A (en) | Production method of Chinese wolfberry fruit tablet candy | |
| CN101297704B (en) | Health care food for protecting liver and manufacturing method thereof | |
| CN105495602A (en) | Preparation method for radix ginseng rubra cell-wall breaking superfine powder particles | |
| CN107048381A (en) | A kind of health food for improving sleep and preparation method thereof | |
| CN103005435B (en) | Anti-fatigue composition capable of improving speed endurance and preparation containing anti-fatigue composition | |
| CN102144696A (en) | Tea with effects of nourishing yin and restoring vitality | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN103463177A (en) | Traditional Chinese medicine health care product for improving and enhancing organism immunity | |
| CN103110114B (en) | Beta-alanine-containing composition for endurance increase, and preparation thereof | |
| CN107961293A (en) | A kind of sea-buckthorn tomato piece and preparation method thereof | |
| CN107412618A (en) | A kind of sealwort American ginseng health preserving tea and preparation method thereof | |
| CN103584092A (en) | Health-care composition | |
| CN105101817A (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
| CN104055115B (en) | A kind of health products containing agate coffee, the stem of noble dendrobium and Panax Japonicus Var. Major and preparation method thereof | |
| CN107536016B (en) | A nutritional food for protecting heart and promoting liver health | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN101731624B (en) | Compound male silkworm moth health-care food for resisting senility and regulating immunity and preparation method | |
| CN101129192A (en) | Cordyceps sinensis highland barley coarse sizing particle and method of preparing the same | |
| CN103751692B (en) | Special invigorating capsule of a kind of Testis et penis callorhini and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Qigeng Inventor after: Xu Yue Inventor before: Xu Yue |
|
| CB03 | Change of inventor or designer information |